IL154642A0 - Treatment of urinary dysfunction - Google Patents

Treatment of urinary dysfunction

Info

Publication number
IL154642A0
IL154642A0 IL15464201A IL15464201A IL154642A0 IL 154642 A0 IL154642 A0 IL 154642A0 IL 15464201 A IL15464201 A IL 15464201A IL 15464201 A IL15464201 A IL 15464201A IL 154642 A0 IL154642 A0 IL 154642A0
Authority
IL
Israel
Prior art keywords
treatment
urinary dysfunction
urinary
dysfunction
Prior art date
Application number
IL15464201A
Other languages
English (en)
Original Assignee
Intreat Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intreat Pty Ltd filed Critical Intreat Pty Ltd
Publication of IL154642A0 publication Critical patent/IL154642A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IL15464201A 2000-08-28 2001-08-28 Treatment of urinary dysfunction IL154642A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ9687A AUPQ968700A0 (en) 2000-08-28 2000-08-28 Treatment of urinary incontinence
PCT/AU2001/001079 WO2002017929A1 (en) 2000-08-28 2001-08-28 Treatment of urinary dysfunction

Publications (1)

Publication Number Publication Date
IL154642A0 true IL154642A0 (en) 2003-09-17

Family

ID=3823741

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15464201A IL154642A0 (en) 2000-08-28 2001-08-28 Treatment of urinary dysfunction

Country Status (19)

Country Link
US (1) US20040067967A1 (xx)
EP (1) EP1315503A4 (xx)
JP (1) JP2004506744A (xx)
KR (1) KR20030034162A (xx)
CN (2) CN101164541A (xx)
AU (1) AUPQ968700A0 (xx)
BR (1) BR0113667A (xx)
CA (1) CA2420846A1 (xx)
CZ (1) CZ2003807A3 (xx)
EA (1) EA007092B1 (xx)
EE (1) EE200300082A (xx)
HU (1) HUP0300860A3 (xx)
IL (1) IL154642A0 (xx)
MX (1) MXPA03001833A (xx)
NO (1) NO20030978L (xx)
NZ (1) NZ537643A (xx)
PL (1) PL360368A1 (xx)
WO (1) WO2002017929A1 (xx)
ZA (1) ZA200302340B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148394A1 (en) * 2002-01-18 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058, or 6351 molecules
US20050143323A1 (en) * 2003-12-30 2005-06-30 Henley E. C. Isoflavone therapy for treating urinary incontinence
KR100462173B1 (ko) * 2004-06-08 2004-12-16 안국약품 주식회사 요실금 예방 및 치료용 조성물
US20060039971A1 (en) * 2004-08-19 2006-02-23 Lee Robert E Effervescent composition including alternative hormone replacement therapy agent
JP4987871B2 (ja) * 2005-08-15 2012-07-25 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３アンタゴニストとしてのピペリジン及びピペラジン誘導体
WO2007143607A2 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
BRPI0719955B1 (pt) * 2006-10-04 2024-01-09 F. Hoffmann-La Roche Ag Processo para síntese de derivados de fenóxi diaminopirimidina
US8277426B2 (en) 2009-09-30 2012-10-02 Wilcox Heather J Male urinary incontinence device
JP7127021B2 (ja) 2016-10-21 2022-08-29 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 細胞傷害性粒子
JP6813717B1 (ja) * 2019-10-02 2021-01-13 あすか製薬株式会社 排尿障害改善剤
WO2021065027A1 (ja) * 2019-10-02 2021-04-08 あすか製薬株式会社 排尿障害改善剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985603A (en) * 1994-05-27 1999-11-16 Glaxo Group Limited P2x receptor DNA and protein sequence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US5856129A (en) * 1996-10-30 1999-01-05 Incyte Pharmaceuticals, Inc. DNA encoding a human purinoceptor

Also Published As

Publication number Publication date
EA200300264A1 (ru) 2003-10-30
EA007092B1 (ru) 2006-06-30
NO20030978D0 (no) 2003-02-28
HUP0300860A3 (en) 2005-03-29
EP1315503A4 (en) 2005-02-09
ZA200302340B (en) 2004-06-28
KR20030034162A (ko) 2003-05-01
EP1315503A1 (en) 2003-06-04
PL360368A1 (en) 2004-09-06
NZ537643A (en) 2006-04-28
MXPA03001833A (es) 2004-11-01
EE200300082A (et) 2004-12-15
BR0113667A (pt) 2003-06-03
CN101164541A (zh) 2008-04-23
HUP0300860A2 (hu) 2003-11-28
WO2002017929A1 (en) 2002-03-07
CA2420846A1 (en) 2002-03-07
US20040067967A1 (en) 2004-04-08
NO20030978L (no) 2003-04-16
CZ2003807A3 (cs) 2003-08-13
CN1479621A (zh) 2004-03-03
AUPQ968700A0 (en) 2000-09-21
JP2004506744A (ja) 2004-03-04

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
IL153492A0 (en) Treatment of male sexual dysfunction
GB0014969D0 (en) Novel method of treatment
HUP0300347A3 (en) Improved treatment of neovascularization
IL154642A0 (en) Treatment of urinary dysfunction
HUP0302430A3 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontience
HRP20020729A2 (en) Treatment of psoriasis
PL362980A1 (en) Treatment of sexual dysfunction
IL155775A0 (en) Treatment of male sexual dysfunction
GB0008921D0 (en) Method of treatment
AU8160701A (en) Treatment of urinary dysfunction
EP1303281A4 (en) METHODS OF TREATMENT
AU2001281607A1 (en) Treatment of urinary dysfunction
AU1079402A (en) Wastewater treatment
GB0025655D0 (en) Sludge treatment
GB0011926D0 (en) Treatment of sexual dysfunction
GB0127006D0 (en) Treatment of moccasion seam
AU6191201A (en) Treatment of effluent
GB0013928D0 (en) Methods of treatment
GB0014904D0 (en) Methods of treatment
TW417741U (en) Improved structure of faucet body
GB0017952D0 (en) Treatment of dyskinesia
AU2002219247A1 (en) Use of levosimendan for treating erictile dysfunction
GB0126904D0 (en) Treatment of sexual dysfunction
GB0111037D0 (en) Treatment of sexual dysfunction